attachment
attachment
attachment
attachment

40 year female with BCVA 6/12, BOTH EYES, ATTACHED IS TGE TOPOGRAPHY. What should be the next step in the management?

Reading File
analyse_media
analyse_media
Finding Sources
Searching PubMed

keratoconus management corneal collagen crosslinking

Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have all the data needed. Let me synthesize a comprehensive answer.

Topography Interpretation + Next Steps

What the Topography Shows

Both eyes (OU) - Scheimpflug Corneal Mapping (Pentacam-type)
OS (Left Eye) - Confirmed Keratoconus:
  • K readings (anterior): K-flat 44.60 D @ 153°, K-steep 48.65 D @ 63°, SimK steep 49.75 D @ 57°
  • K-max: 51.09 D - indicating moderate-to-advanced keratoconus (>48 D = moderate; >54 D = severe)
  • Corneal thickness minimum (Thk-min: 401 µm) - significantly thinned
  • Posterior elevation: markedly elevated (hot spot on posterior elevation map)
  • Anterior elevation: focal area of high positive elevation
  • Keratoconus Screening classification: KERATOCONUS (red flags on all curvature indices - SIf, CSIf, SIb, CSIb all red-dotted)
  • Tangential curvature map: Classic inferior-paracentral steepening cone pattern
OD (Right Eye) - Confirmed Keratoconus:
  • K readings (anterior): K-flat 44.71 D @ 26°, K-steep 50.63 D @ 116°, SimK steep 52.90 D
  • K-max: 54.42 D - severe keratoconus range
  • Corneal thickness minimum (Thk-min: 384 µm) - severely thinned
  • Posterior elevation: dramatically elevated (large area of high positive posterior elevation, values >+283 µm visible)
  • Keratoconus screening: KERATOCONUS (all indices red-dotted)
  • Classification: Keratoconus, more advanced than OS
Summary: Bilateral keratoconus - OD more severe (K-max ~54 D, Thk-min 384 µm), OS moderate-severe (K-max ~51 D, Thk-min 401 µm). Both eyes show significant posterior elevation, anterior elevation, and marked corneal thinning consistent with the device's own "Keratoconus" classification.

Next Steps in Management

Step 1 - Immediate: Assess for Progression (Most Critical)

The most important question before any intervention is: Is the keratoconus progressive?
  • Obtain serial topographies (compare with any prior Pentacam/Orbscan maps). Progression is defined as:
    • Increase in K-max of ≥1.0 D over 12 months
    • Decrease in minimum corneal thickness of ≥2% over 12 months
    • Increase in manifest cylinder
    • Worsening BCVA
  • If this is the first topography, repeat it in 3-6 months to establish progression. However, given the patient's age (40 years), the BCVA (6/12 both eyes), and the severity on the maps, the clinical priority below still holds.

Step 2 - Corneal Cross-Linking (CXL) Assessment

Given bilateral confirmed keratoconus with reduced BCVA (6/12 OU), CXL should be strongly considered:
  • CXL is indicated if progression is documented (or suspected given no prior data and this severity at age 40)
  • Standard Dresden protocol (epithelium-off): 9 mm epithelial debridement, riboflavin 0.1% drops for 30 min, then UVA 365 nm at 3 mW/cm² for 30 min (5.4 J/cm² total)
  • Minimum corneal thickness requirement: ≥400 µm (after epithelial removal/swelling)
    • OS: Thk-min 401 µm - borderline, may need hypo-osmolar riboflavin to swell the stroma to ≥400 µm before UVA
    • OD: Thk-min 384 µm - below the conventional safe threshold. Accelerated or modified protocols, or hypoosmolar riboflavin pre-treatment to achieve ≥400 µm, must be used. This is a critical safety consideration.
  • CXL is successful in halting progression in >90% of cases and can even partially reverse ectasia (Kanski's Clinical Ophthalmology, 10th ed.)

Step 3 - Visual Rehabilitation

The patient currently sees 6/12 (20/40) OU with best-corrected vision. Management of vision:
  1. Spectacles - Useful if the irregular astigmatism is not too severe. Given the K values, spectacles alone may be insufficient for best acuity.
  2. Rigid Gas Permeable (RGP) contact lenses - First-line for moderate keratoconus. Vaults the irregular cone and provides a regular refracting surface.
  3. Scleral contact lenses - Better option for advanced/irregular cases; vaults the cone entirely, very well tolerated.
  4. Hybrid lenses or piggyback lenses - Alternatives if RGP tolerance is poor.
Given this patient has moderate-severe bilateral KC with 6/12 BCVA, an RGP or scleral lens trial should be done to determine if BCVA improves with a regular refracting surface. If BCVA improves significantly with RGP/scleral lenses, visual rehabilitation is the priority alongside stabilization.

Step 4 - Counseling

  • Strict no-eye-rubbing counseling - This is non-negotiable. Eye rubbing is a major risk factor for progression.
  • Treat any associated atopy/allergy aggressively (antihistamines, mast cell stabilizers)
  • Genetic counseling awareness - 10% risk in offspring

Step 5 - If Contact Lenses Fail (Advanced Disease Management)

  • Intracorneal ring segments (ICRS) - e.g., Intacs, Ferrara rings. Can regularize the cornea and improve contact lens tolerance. Can be combined with CXL ("ICRS + CXL" or "corneal remodeling + stabilization" approach).
  • Keratoplasty (if contact lenses are not tolerated and disease is too advanced):
    • DALK (Deep Anterior Lamellar Keratoplasty) - preferred; preserves host endothelium, lower rejection risk
    • PKP (Penetrating Keratoplasty) - reserved for cases with endothelial compromise or prior hydrops with Descemet membrane rupture
    • Note: LASIK is absolutely contraindicated in keratoconus

Recommended Action Plan Summary

PriorityActionRationale
1Slit-lamp exam (Vogt striae, Fleischer ring, scarring, hydrops)Complete clinical picture
2Review/obtain prior topographies to confirm progressionDefines CXL urgency
3Trial of RGP or scleral contact lensesImprove BCVA 6/12
4CXL - plan for both eyes (OD caution re: 384 µm)Halt progression
5Strict no-rubbing + allergy managementPrevent acceleration
Key point for OD: The minimum corneal thickness of 384 µm in OD is below the standard CXL safety threshold of 400 µm. Hypo-osmolar riboflavin protocol or alternative accelerated CXL protocols should be considered and discussed with a corneal specialist before proceeding.

Sources: Kanski's Clinical Ophthalmology: A Systematic Approach, 10th ed. - Wills Eye Manual, 8th ed. | Recent evidence: Epithelium-on vs epithelium-off CXL meta-analysis 2025 (PMID 40856685)
This is a shared conversation. Sign in to Orris to start your own chat.